BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 34464510)

  • 21. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
    Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
    Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
    Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
    Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
    Yang XR; Chang-Claude J; Goode EL; Couch FJ; Nevanlinna H; Milne RL; Gaudet M; Schmidt MK; Broeks A; Cox A; Fasching PA; Hein R; Spurdle AB; Blows F; Driver K; Flesch-Janys D; Heinz J; Sinn P; Vrieling A; Heikkinen T; Aittomäki K; Heikkilä P; Blomqvist C; Lissowska J; Peplonska B; Chanock S; Figueroa J; Brinton L; Hall P; Czene K; Humphreys K; Darabi H; Liu J; Van 't Veer LJ; van Leeuwen FE; Andrulis IL; Glendon G; Knight JA; Mulligan AM; O'Malley FP; Weerasooriya N; John EM; Beckmann MW; Hartmann A; Weihbrecht SB; Wachter DL; Jud SM; Loehberg CR; Baglietto L; English DR; Giles GG; McLean CA; Severi G; Lambrechts D; Vandorpe T; Weltens C; Paridaens R; Smeets A; Neven P; Wildiers H; Wang X; Olson JE; Cafourek V; Fredericksen Z; Kosel M; Vachon C; Cramp HE; Connley D; Cross SS; Balasubramanian SP; Reed MW; Dörk T; Bremer M; Meyer A; Karstens JH; Ay A; Park-Simon TW; Hillemanns P; Arias Pérez JI; Menéndez Rodríguez P; Zamora P; Benítez J; Ko YD; Fischer HP; Hamann U; Pesch B; Brüning T; Justenhoven C; Brauch H; Eccles DM; Tapper WJ; Gerty SM; Sawyer EJ; Tomlinson IP; Jones A; Kerin M; Miller N; McInerney N; Anton-Culver H; Ziogas A; Shen CY; Hsiung CN; Wu PE; Yang SL; Yu JC; Chen ST; Hsu GC; Haiman CA; Henderson BE; Le Marchand L; Kolonel LN; Lindblom A; Margolin S; Jakubowska A; Lubiński J; Huzarski T; Byrski T; Górski B; Gronwald J; Hooning MJ; Hollestelle A; van den Ouweland AM; Jager A; Kriege M; Tilanus-Linthorst MM; Collée M; Wang-Gohrke S; Pylkäs K; Jukkola-Vuorinen A; Mononen K; Grip M; Hirvikoski P; Winqvist R; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Auvinen P; Soini Y; Sironen R; Bojesen SE; Ørsted DD; Kaur-Knudsen D; Flyger H; Nordestgaard BG; Holland H; Chenevix-Trench G; Manoukian S; Barile M; Radice P; Hankinson SE; Hunter DJ; Tamimi R; Sangrajrang S; Brennan P; McKay J; Odefrey F; Gaborieau V; Devilee P; Huijts PE; Tollenaar RA; Seynaeve C; Dite GS; Apicella C; Hopper JL; Hammet F; Tsimiklis H; Smith LD; Southey MC; Humphreys MK; Easton D; Pharoah P; Sherman ME; Garcia-Closas M
    J Natl Cancer Inst; 2011 Feb; 103(3):250-63. PubMed ID: 21191117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
    Kawai M; Malone KE; Tang MT; Li CI
    Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for breast cancer subtypes among Black women undergoing screening mammography.
    Friebel-Klingner TM; Ehsan S; Conant EF; Kontos D; Domchek SM; McCarthy AM
    Breast Cancer Res Treat; 2021 Oct; 189(3):827-835. PubMed ID: 34342765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.
    Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
    Cancer Causes Control; 2011 Mar; 22(3):399-405. PubMed ID: 21184265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
    Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
    BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
    Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
    Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
    Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
    Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    Sengal AT; Haj-Mukhtar NS; Elhaj AM; Bedri S; Kantelhardt EJ; Mohamedani AA
    BMC Cancer; 2017 Dec; 17(1):804. PubMed ID: 29191181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.